Hookipa Pharma Inc/HOOK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Hookipa Pharma Inc

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Ticker

HOOK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joern Aldag

Employees

151

Headquarters

New york, United States

HOOK Metrics

BasicAdvanced
$79M
Market cap
-
P/E ratio
-$0.59
EPS
0.75
Beta
-
Dividend rate
$79M
0.74867
$1.27
$0.41
841K
4.497
1.095
-30.76%
-50.55%
-40.40%
1.467
0.752
0.752
235.12%
49.74%
0.92%

What the Analysts think about HOOK

Analyst Ratings

Majority rating from 6 analysts.
Buy

HOOK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
39.17% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$37M
393.24%
Net income
$14M
-157.66%
Profit margin
39.17%
-111.69%

HOOK Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 207.32%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.22
-$0.17
-$0.22
$0.11
-
Expected
-$0.21
-$0.21
-$0.19
-$0.10
-$0.12
Surprise
5.35%
-19.05%
13.99%
-207.32%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Hookipa Pharma Inc stock?

Hookipa Pharma Inc (HOOK) has a market cap of $79M as of June 20, 2024.

What is the P/E ratio for Hookipa Pharma Inc stock?

The price to earnings (P/E) ratio for Hookipa Pharma Inc (HOOK) stock is 0 as of June 20, 2024.

Does Hookipa Pharma Inc stock pay dividends?

No, Hookipa Pharma Inc (HOOK) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Hookipa Pharma Inc dividend payment date?

Hookipa Pharma Inc (HOOK) stock does not pay dividends to its shareholders.

What is the beta indicator for Hookipa Pharma Inc?

Hookipa Pharma Inc (HOOK) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Hookipa Pharma Inc stock price target?

The target price for Hookipa Pharma Inc (HOOK) stock is $4.33, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Hookipa Pharma Inc stock

Buy or sell Hookipa Pharma Inc stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing